IMV.TOTSXHealthcare · Biotechnology

IMV Inc.

$1.12+0.00%(+$0.00)

TickerSpark Score

54/100

Mixed

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMV.TO research report →

52-Week Range4% of range

Low $0.62

Current $1.12

High $13.10

Companywww.imv-inc.com

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers.

CEO: Andrew Hall
IPO: 2007
Employees: 63
HQ: Dartmouth, NS, CA

Price Chart

-91.45% · this period

Valuation

Market Cap: $13.12M
P/E: -0.18
P/S: 0.00
P/B: -1.03
EV/EBITDA: -0.47
Div Yield: 0.00%

Profitability

Gross Margin: 0.00%
Op Margin: 0.00%
Net Margin: 0.00%
ROE: -495.17%
ROIC: -172.47%

Growth & Income

Revenue: $0 · 0.00%
Net Income: $-36,989,000 · 1.35%
EPS: $-4.43 · 12.28%
Op Income: $-39,494,000
FCF YoY: -3.06%

Performance & Tape

52W High: $13.10
52W Low: $0.62
50D MA: $1.03
200D MA: $3.21
Beta: 1.52
Avg Volume: 13.81K

Get TickerSpark's AI analysis on IMV.TO

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime